Why Do Patients Develop Proteinuria With Sirolimus? Do We Have the Answer?

American Journal of Kidney Diseases

Volumn 55, Issue 2, 2010, Pages 213-216

  Chapman, Jeremy R ^a   Rangan, Gopala K ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; TRANSFERRIN; VASCULOTROPIN;

ALBUMIN BLOOD LEVEL; CLINICAL TRIAL; EDITORIAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PROTEIN URINE LEVEL; PROTEINURIA; TRANSFERRIN BLOOD LEVEL;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEINURIA; SIROLIMUS;

EID: 74549126028     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.003     Document Type: Editorial

References (21)

1. Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc 36 suppl 2 (2004) 220S-223S
2. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 349 24 (2003) 2326-2333
3. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 5 (1998) 335-340
4. Lee V.W., and Chapman J.R. Sirolimus: its role in nephrology. Nephrology (Carlton) 10 6 (2005) 606-614
5. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 11 (2005) 2517-2523
6. Kuypers D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28 2 (2005) 153-181
7. Ducloux D., Motte G., Billerey C., et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int 15 8 (2002) 387-392
8. Franz S., Regeniter A., Hopfer H., Mihatsch M.J., and Dickenmann M. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosupression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 55 2 (2010) 335-343
9. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med 357 25 (2007) 2562-2575
10. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87 2 (2009) 233-242
11. Russ G., Segoloni G., Oberbauer R., et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 80 9 (2005) 1204-1211
12. Russ G., Campbell S., Chadban S., et al., Members of the Wyeth Australia Transplant Advisory Board. Sirolimus: an expert panel guide on who and how to convert renal transplant patients from a CNI- to sirolimus-based regimen, including management of key adverse events (version 2) (October 2006)
13. Augustine J.J., Bodziak K.A., and Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 67 3 (2007) 369-391
14. Gutierrez-Dalmau A., and Campistol J.M. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 22 suppl 1 (2007) i11-i16
15. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 2 (2006) 581-589
16. Vollenbroker B., George B., Wolfgart M., Saleem M.A., Pavenstadt H., and Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol 296 2 (2009) F418-F426
17. Letavernier E., Bruneval P., Vandermeersch S., et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24 2 (2008) 630-638
18. Lieberthal W., Fuhro R., Andry C., Patel V., and Levine J.S. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 82 1 (2006) 17-22
19. Lieberthal W., Fuhro R., Andry C.C., et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol 281 4 (2001) F693-F706
20. Smith K.D., Wrenshall L.E., Nicosia R.F., et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14 4 (2003) 1037-1045
21. Straathof-Galema L., Wetzels J.F., Dijkman H.B., Steenbergen E.J., and Hilbrands L.B. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 6 2 (2006) 429-433